Nurix Therapeutics Inc [NRIX] stock is trading at $25.44, up 2.58%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NRIX shares have gain 8.53% over the last week, with a monthly amount glided 14.80%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on July 31, 2024, and set its price target to $36. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $20 on March 09, 2023. Oppenheimer initiated its recommendation with a Outperform and recommended $25 as its price target on February 28, 2023. Morgan Stanley started tracking with a Equal-Weight rating for this stock on October 11, 2022, and assigned it a price target of $11. In a note dated May 31, 2022, Wells Fargo upgraded an Overweight rating on this stock but restated the target price of $25.
Nurix Therapeutics Inc [NRIX] stock has fluctuated between $4.22 and $26.12 over the past year. Currently, Wall Street analysts expect the stock to reach $27.57 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $25.44 at the most recent close of the market. An investor can expect a potential return of 8.37% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 62.30M for the trailing twelve months, which represents a drop of -60.58%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -2.87%, Pretax Profit Margin comes in at -2.65%, and Net Profit Margin reading is -2.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.68 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.76 points at the first support level, and at 24.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.10, and for the 2nd resistance point, it is at 26.76.
Ratios To Look Out For
For context, Nurix Therapeutics Inc’s Current Ratio is 5.57. As well, the Quick Ratio is 5.57, while the Cash Ratio is 1.45. Considering the valuation of this stock, the price to sales ratio is 26.30, the price to book ratio is 4.42.
Transactions by insiders
Recent insider trading involved Ring Christine, Chief Legal Officer, that happened on Sep 03 ’24 when 9050.0 shares were sold. Officer, CHRISTINE RING completed a deal on Sep 03 ’24 to buy 9050.0 shares. Meanwhile, Chief Legal Officer Ring Christine sold 9870.0 shares on Aug 26 ’24.
